ArticleInternational journal of general medicine2025
Alterations in the Gut Microbiota of Patients with Esophageal Squamous Cell Carcinoma: A Cross-Sectional Study Conducted in a High-Incidence Region of China.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring the characteristics of gut microbiome changes in lung cancer patients and healthy controls.Scientific reports · 2026Article
- Serum Untargeted Metabolomics Profiling of Esophageal Squamous Cell Carcinoma in High-Incidence Areas of China.International journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is an aggressive and often fatal upper gastrointestinal cancer. Although the gut microbiota plays a critical role in the development of digestive tract malignancies, especially those in the lower gastrointestinal tract, clinical studies exploring its association with ESCC remain limited. Objective: This study aimed to delineate differences in gut microbiota diversity and composition between ESCC patients and healthy controls (HCs) through full-length 16S rRNA sequencing. Methods: Between September 2023 and September 2024, 171 fresh fecal samples were obtained from 93 patients with ESCC and 78 HCs in Hebei Province, China. Sequencing of the full-length 16S rRNA gene regions (V1-V9) was conducted using the PacBio Sequel II platform, followed by comprehensive bioinformatic analysis. Results: Relative to HCs, ESCC patients exhibited markedly lower alpha diversity and distinct beta diversity. At the genus level, enrichment of Conclusion: Comprehensive analysis of the gut microbial community in ESCC patients from Hebei Province, China, revealed significant dysbiosis involving community structure, bacterial phenotypes, functional capacity, and metabolic pathways. These alterations may be potentially associated with the occurrence of ESCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.